Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 845

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 845
---
       |     |      |       |
| Warrants to purchase common stock               |     |               | 2,560 |     |      |   533 |
| Common stock options                            |     |               | 1,975 |     |      |   733 |
| Vested restricted stock subject to recall       |     |               |    56 |     |      |    56 |
| Unvested restricted stock subject to repurchase |     |               |     8 |     |      |   175 |
| Total                                           |     |               | 4,599 |     |      | 1,497 |

Defined Contribution Plan The Company sponsors a 401(k) Plan whereby all employees are eligible to participate in the 401(k) Plan after meeting certain eligibility requirements. Participants may elect to have a portion of their salary deferred and contributed to the 401(k) plan, subject to certain limitations. The Company provided matching contributions of $115,000 for the year ended December 31, 2023 and $129,000 for the year ended December 31, 2022. F-116

#### KINETA, INC.Notes to Consolidated Financial Statements16. Related Party TransactionsStock PurchasesDuring the year ended December 31, 2023, five members of the Company’s executive management purchased 43,000 shares of the Company’s common stock on the open market and one director of the Company purchased 5,000 shares of the Company’s common stock on the open market.RSU VestingDuring the year ended December 31, 2023, the Company issued 123,000 shares of its common stock to members of the Company’s executive management and 10,000 shares to directors of the Company, upon vesting of restricted stock units.Warrant ExercisesDuring the year ended December 31, 2023, the Company issued 3,000 shares of its common stock to members of the Company’s executive management and 64,000 shares to a director of the Company, upon exercise of outstanding warrants. During the year ended December 31, 2022, the Company issued 43,000 shares of its common stock to a director of the Company, upon exercise of outstanding warrants.Private PlacementIn December 2022, the Company issued415,000 shares of its common stock for an aggregate purchase price of $4.8 million to four related parties and issued 66,000 warrants to purchase shares of the Company’snon-votingcommon stock to the same